Myelodysplastic Syndromes (MDS) Clinical Trials

Stanford University School of Medicine
Stanford California 94305

A Phase 2 clinical study for patients with Leukemia, Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Rocky Mountain Cancer Centers
Denver Colorado 80218

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

H. Lee Moffitt Cancer Center and Research Institute
Tampa Florida 33612

A clinical trial seeking patients for a research study for the treatment of Myelodysplastic Syndromes

H. Lee Moffitt Cancer Center
Tampa Florida 33602

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Johns Hopkins University
Baltimore Maryland 21231

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Dana-Farber Cancer Institute/Brigham and Women's Hospital
Boston Massachusetts 02215

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

North Shore-LIJ Health System Monter Cancer Center
Lake Success New York 11020

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Columbia University Medical Center
New York New York 10032

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Cleveland Clinic Foundation
Cleveland Ohio 44195

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Sarah Cannon Research Institute
Nashville Tennessee 37203

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

The University of Texas, MD Anderson Cancer Center
Houston Texas 77030

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Texas Oncology
Round Rock Texas 78681

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Texas Oncology
Tyler Texas 75702

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Virginia Oncology Associates
Norfolk Virginia 23502

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Yakima Valley Memorial Hospital/North Star Lodge
Yakima Washington 98902

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Peter MacCallum Cancer Centre
East Melbourne Victoria 3002

A clinical research study of Azacitidine and eltrombopag for the treatment of Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML)

Cabrini Hospital
Malvern Victoria 3144

A clinical research study of Azacitidine and eltrombopag for the treatment of Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML)

Centre Hospitalier Universitaire Hôpital Avicenne
Bobigny 93009

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

CHRU de Lille -Hôpital Claude Huriez Service des Maladies du Sang
Lille 59037

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

CHU De Nantes
Nanes 44000

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Hôpital Cochin
Paris Cedex 75001

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Centre de Recherche en Cancerologie de Marseille- Institute Paoli Calmettes
Rouen 13273

Patients are needed to participate in a clinical research study evaluating Sotatercept 0.1 mg/kg, Sotatercept 0.3 mg/kg and Sotatercept 0.5 mg/kg for the treatment of Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Low to Intermediate-1 MDS

Novartis Investigative Site
Chuo-ku Tokyo 104-0045

A clinical research study of Panobinostat for the treatment of Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML)

Novartis Investigative Site
Kashiwa Chiba 277-8577

A clinical research study of Panobinostat for the treatment of Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML)

Novartis Investigative Site
Kobe Hyogo 650-0017

A clinical research study of Panobinostat for the treatment of Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML)

Novartis Investigative Site
Kyoto 602-0841

A clinical research study of Panobinostat for the treatment of Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML)

Novartis Investigative Site
Nagoya Aichi 466-8650

A clinical research study of Panobinostat for the treatment of Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML)